News

PURE Hard Surface has been assigned the drug identification number (DIN) 02368803. The company claims US EPA-registered PURE Hard Surface kills resistant pathogens like MRSA and also eliminates

The company expects to assess the antiviral activity, tolerability and safety of ACH-1625 in conjunction with standard of care (SOC) consisting of pegylated interferon alfa-2a and ribavirin. In

ImmunoCellular received patent no. 7,939,090, entitled ‘System and method for the treatment of cancer, including cancers of the central nervous system,’ that covers the combination of a dendritic

Under the agreement, CCRI and SIOPEN licensed Apeiron to further develop the drug which is indicated for the treatment of high-risk neuroblastoma. The agreement also allows Apeiron for

The new patent entitled, ‘Nucleoside Phosphoramidate Prodrugs,’ is related to the composition and matter of PSI-7977 and its diastereomeric mixture indicated for the treatment of hepatitis C virus

Under the agreement, Pharmatech will use all its expertise and experience in regulatory affairs to help the Chinese manufacturer to meet the required compliance demanded by the regulatory

Seaside Therapeutics expects to recruit around 150 patients in 25 clinical sites in the US. In the study patients will be randomized to receive either STX209 or placebo.

Currently, the company is developing hGH-CTP in Phase II trial as a treatment for growth harmone deficiency in children. Earlier, Prolor has released interim results from a Phase

The nutrition research program will be conducted in collaboration with a strategic partner, the Institute of Nutraceuticals and Functional Foods (INAF). INAF dedicates all of its research efforts